1. PH 1 TRIAL EVALUATING MRG‐106, A MICRORNA‐155 INHIBITOR, ADMINISTERED BY INTRATUMORAL, SUBCUTANEOUS, OR INTRAVENOUS DELIVERY IN CUTANEOUS T‐CELL LYMPHOMA (CTCL) PATIENTS. (June 2017) Authors: Querfeld, C.; Foss, F.M.; Porcu, P.; Kim, Y.H.; Pacheco, T.; Haverkos, B.; Halwani, A.S.; DeSimone, J.; William, B.; Pinter‐Brown, L.; Seto, A.; Ruckman, J.; Landry, M.; Jackson, A.L.; Dickinson, B.; Sanseverino, M.; Rodman, D.; Rubin, P.; Marshall, W.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 275 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗